Endophthalmitis:
The Most Feared Complication
of Cataract Surgery
And what every patient, surgeon, and distributor needs to understand about it
One in a thousand cataract surgeries ends in infection. When it does, the eye may never recover. Here is the biology, the evidence, and the three-letter word that prevents most of it.
What endophthalmitis is — and why surgeons lose sleep over it
The word comes from the Greek endon (within) and ophthalmos (eye). Endophthalmitis is an infection inside the eye — specifically a microbial colonisation of the vitreous cavity and anterior chamber. It is not an eye infection in the conventional sense. This is not pink eye. It is bacteria or fungi multiplying inside a structure that has almost no ability to defend itself.
The eye is an immunologically privileged site. It has limited access to circulating immune cells because the blood-retinal barrier, which protects it from inflammation under normal conditions, also prevents the immune system from mounting a rapid response once infection is established. By the time the eye signals distress — pain, vision loss, hypopyon — the infection is already significant.
After cataract surgery, endophthalmitis typically presents in two forms. Acute-onset (within 6 weeks of surgery, usually within days) is the most common and most dangerous — caused by virulent bacteria that enter the eye during or immediately after the procedure. Delayed-onset (weeks to months post-operatively) is typically caused by less virulent organisms and has a slower, more insidious clinical course.
This is an ophthalmic emergency
Any patient who has had cataract surgery within the past 6 weeks and presents with sudden vision worsening, eye pain, and redness should be treated as endophthalmitis until proven otherwise. This is a same-day emergency. Delay in diagnosis directly worsens the visual outcome. Immediate referral to an ophthalmologist for intravitreal antibiotic injection is the most important intervention.
How common it is — and what outcomes look like
The global incidence of post-cataract endophthalmitis sits at approximately 0.07–0.1% in surgical centres without intracameral antibiotic protocols. In absolute terms — with 20 million cataract surgeries performed annually — that translates to 14,000 to 20,000 cases of endophthalmitis every single year, worldwide. Most of these are preventable.
The AIIMS multicenter RCT published in October 2025 is the largest randomised controlled trial ever conducted on this question: 30,000 phacoemulsification cases across tertiary eye centres in India. Without intracameral prophylaxis, 16 cases of endophthalmitis occurred in 30,000 eyes (0.05%). With intracameral moxifloxacin: 6 cases in 30,000 eyes (0.02%). A 2.5-fold reduction. Statistically significant at p=0.04.
But the more sobering number is what happens when endophthalmitis does occur. The same study's follow-up data showed that at 3 months, 77% of affected eyes responded to treatment — leaving 23% that did not. Of those non-responding cases, 18% developed phthisis bulbi. One case progressed to panophthalmitis. These are not statistics. These are individual eyes that will never see again.
The antibiotic resistance question
A common concern about intracameral antibiotic use is antibiotic resistance. The AIIMS data addressed this directly: moxifloxacin resistance among causative organisms was 28.5% — the lowest of any tested fluoroquinolone. Ciprofloxacin resistance was 75%. A 2025 medRxiv preprint from a Brazilian university hospital found that moxifloxacin resistance remained stable (pre: 45.5%; post: no increase) after years of prophylactic use — contradicting fears that widespread intracameral use would rapidly select for resistant organisms.
What is actually causing the infection
Understanding the microbiology of endophthalmitis matters because it determines which antibiotics work — and why moxifloxacin's broad spectrum is clinically important.
| Organism | Frequency | Source | Moxifloxacin Susceptibility |
|---|---|---|---|
| Staphylococcus epidermidis | Most common (36–52%) | Patient's own ocular flora | High — covers well |
| Staphylococcus aureus | 10–15% | Skin, nasolacrimal flora | Good — MRSA variable |
| Streptococcal species | 9–12% | Oral/respiratory flora | Good coverage |
| Pseudomonas aeruginosa | 8–10% | Environment, water | Variable — monitor |
| Gram-negative bacilli (others) | 5–8% | Environment | Generally covers |
| Fungal (Candida, Aspergillus) | <5% (delayed onset) | Environment, systemic | Antibiotics ineffective — antifungals required |
The key clinical insight is this: the vast majority of post-cataract endophthalmitis is caused by bacteria from the patient's own periocular flora — organisms that already live on the eyelid margins, conjunctiva, and in the nasolacrimal drainage system. The bacteria do not come primarily from the surgical environment or instruments. They come from the patient.
This is why the surgery's opening step — povidone-iodine preparation of the ocular surface and surrounding skin — is irreplaceable. And it is why a drug injected inside the eye, where the flora are heading, is more effective than a drop sitting on the surface.
Who is most at risk
Not all cataract patients face equal endophthalmitis risk. The single strongest risk factor identified across multiple studies is intraoperative posterior capsular rupture — associated with a 3.68-fold increase in endophthalmitis risk in the Kaiser Permanente study of 315,246 procedures. When the posterior capsule tears, the barrier between the anterior segment and the vitreous is lost, giving bacteria direct access to a nutrient-rich, immune-privileged environment.
"Posterior capsular rupture was associated with a 3.68-fold increased risk of endophthalmitis. Intracameral antibiotic was more effective than topical agent alone. Topical antibiotic was not shown to add to the effectiveness of an intracameral regimen."
Beyond surgical complications, the systemic and ocular risk factors include:
- Clear corneal incision — compared to scleral tunnel, has higher incidence in some studies due to potential wound architecture issues
- Silicone IOL material — acrylic IOLs are associated with lower endophthalmitis rates than silicone, per ESCRS data
- Diabetes mellitus — impaired immune response, altered flora, poorer wound healing
- Blepharitis or meibomian gland dysfunction — increased periocular bacterial load
- Nasolacrimal duct obstruction — reservoir of bacteria with direct access to the ocular surface
- Immunosuppression — any cause, including systemic steroids, chemotherapy, or HIV
- High surgical volume with inadequate sterility protocols — endophthalmitis clusters have been documented after systemic contamination of intraocular solutions
The intraocular solution contamination risk
Contaminated intraocular solutions — including viscoelastics, irrigating solutions, and intracameral injectables — have caused documented endophthalmitis clusters. This is why the sourcing and manufacturing quality of these products matters beyond just price. Sterility testing, terminal sterilisation, and GMP-compliant manufacturing are not optional quality markers — they are the direct infection prevention layer at the point of most vulnerability.
Symptoms — what to look for and when to act
The classic presentation of acute post-cataract endophthalmitis is unmistakable once you know what to look for — but it is frequently misattributed to normal post-operative inflammation in its early hours, which is when the window for treatment is most critical.
The presenting triad
- Sudden vision deterioration — the patient had improving vision for days after surgery, then experiences a precipitous drop. This pattern — initial improvement followed by worsening — is the most important clinical signal.
- Pain — unlike normal post-operative discomfort, endophthalmitis pain is severe and progressive. It does not respond to over-the-counter analgesics.
- Redness with discharge — intense conjunctival injection, often with purulent or mucopurulent discharge, eyelid swelling, and chemosis.
The pathognomonic sign
Hypopyon — a visible white fluid level in the inferior anterior chamber caused by accumulation of inflammatory cells and pus. This is the hallmark slit-lamp finding of endophthalmitis. Its presence makes the diagnosis essentially certain.
What patients should do
Any patient within 6 weeks of cataract surgery who experiences sudden vision loss with or without pain should call their surgeon or go to a hospital emergency eye unit on the same day. Do not wait. Do not see if it improves overnight. The difference between presenting at 24 hours and presenting at 72 hours is, in some cases, the difference between a functioning eye and phthisis.
What actually prevents it — and what does not
Prevention of post-cataract endophthalmitis requires a layered approach. No single intervention eliminates risk entirely, but the combination of perioperative antisepsis and intracameral antibiotic prophylaxis reduces it to near-negligible levels.
1. Povidone-iodine antisepsis — non-negotiable
Application of 5% povidone-iodine to the conjunctival sac immediately before surgery remains the single most evidence-supported intervention for endophthalmitis prevention. It reduces periocular bacterial load dramatically. No other antiseptic has equivalent evidence. It is not optional.
2. Intracameral antibiotic injection — the most effective pharmacological intervention
A 2015 meta-analysis of 18 studies found that intracameral antibiotics reduced endophthalmitis incidence from 1 in 485 surgeries (without) to 1 in 2,855 surgeries (with) — a relative risk reduction to 0.12 (p<0.00001). The 2025 ScienceDirect meta-analysis of 5.6 million patients confirmed a 69% risk reduction overall, with moxifloxacin achieving an OR of 0.24 — a 76% reduction. These are among the most robust numbers in surgical prophylaxis anywhere in medicine.
3. Topical antibiotics — evidence is weaker than commonly assumed
Multiple meta-analyses have failed to demonstrate that topical antibiotic drops provide meaningful additional protection over intracameral injection alone. The Herrinton study found that combining topical and intracameral antibiotics was not more effective than intracameral alone. Yet many surgical protocols continue to prescribe topical antibiotics for weeks post-operatively, adding patient burden, cost, and preservative-related ocular surface toxicity without clear benefit.
4. Surgical technique and wound architecture
Well-constructed, self-sealing clear corneal incisions with appropriate tunnel length, and rigorous posterior capsule preservation, are the surgical foundations of endophthalmitis prevention. No antibiotic compensates for a poorly constructed wound or an unrecognised capsular complication.
MOXGUARD — Sterile Intracameral Moxifloxacin
MOXGUARD is Agaaz Ophthalmics' sterile intracameral moxifloxacin solution — formulated specifically for injection into the anterior chamber at the conclusion of cataract surgery. It is not an eye drop. It is not a topical antibiotic. It is a precisely dosed, sterile, intracameral preparation delivering the antibiotic exactly where it is needed: inside the eye, at the surgical site, at the highest-risk moment.
Moxifloxacin is a fourth-generation fluoroquinolone with bactericidal activity against both gram-positive and gram-negative organisms — covering the most common causative pathogens of post-cataract endophthalmitis. Among fluoroquinolones, it has the lowest resistance rates: 28.5% in the AIIMS trial versus 75% for ciprofloxacin. No evidence of corneal endothelial toxicity or excess postoperative inflammation was observed in the AIIMS RCT at any of its 30,000 study eyes.
More from Beyond Vision
Frequently asked questions
Endophthalmitis is a microbial infection inside the eye — specifically within the vitreous cavity and anterior chamber. After cataract surgery, it typically presents within days to weeks as a sudden, severe deterioration in vision accompanied by pain, redness, and often a visible white fluid level (hypopyon) in the anterior chamber. It is the most feared complication of cataract surgery because it can cause permanent vision loss even with prompt treatment.
Without intracameral antibiotic prophylaxis, incidence ranges from approximately 0.1% to 0.2% (1 in 500–1,000 surgeries). With intracameral antibiotic prophylaxis, this falls to approximately 0.02–0.03%. A 2025 meta-analysis of 5.6 million patients found a 69% overall risk reduction with intracameral antibiotics, with moxifloxacin specifically showing a 76% reduction. The 2025 AIIMS RCT of 30,000 cases found a 2.5-fold reduction with intracameral moxifloxacin.
The key warning signs are: sudden worsening of vision after initial improvement, significant eye pain that is getting worse rather than better, intense redness, visible pus in the eye (a white fluid level called hypopyon), and severe eyelid swelling. Any of these within 6 weeks of cataract surgery is a same-day ophthalmic emergency. Do not wait to see if symptoms improve — contact your surgeon or go to an emergency eye unit immediately.
Intracameral moxifloxacin is a sterile antibiotic solution injected directly into the anterior chamber at the end of cataract surgery — not a topical eye drop. The distinction matters enormously: topical drops sit on the ocular surface and achieve very low concentrations inside the eye. Intracameral injection delivers the antibiotic exactly where the infection risk is highest: inside the eye, immediately after the surgical wound is closed. Multiple meta-analyses confirm intracameral injection is significantly more effective than topical drops alone, and that topical antibiotics do not meaningfully add to intracameral prophylaxis.
With prompt treatment — intravitreal antibiotic injection and in some cases vitrectomy — many cases can be controlled. However, the prognosis for vision is highly variable and often poor. The 2025 AIIMS RCT found that 77% of affected eyes responded to treatment at 3 months, but 18% developed phthisis bulbi (permanent non-function) and one case progressed to panophthalmitis. Even successfully treated eyes frequently have permanently reduced visual acuity. This is why prevention via intracameral antibiotic prophylaxis is so much more important than treatment.
Peer-Reviewed References
- Sharma N, Sen A, Sharma M, et al. (2025). Efficacy of intracameral moxifloxacin in prevention of post-cataract surgery endophthalmitis: a randomized control trial. Journal of Cataract and Refractive Surgery. doi:10.1097/j.jcrs.0000000000001788
- Abu-Zaid A, et al. (2026). Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: a systematic review and meta-analysis. Frontiers in Medicine, 12:1704056. doi:10.3389/fmed.2025.1704056
- Friling E, et al. (2024). Effectiveness of intracameral antibiotics in reducing postoperative endophthalmitis risk: a meta-analysis. ScienceDirect. doi:10.1016/j.jtos.2025.01.003
- Herrinton LJ, et al. (2016). Comparative effectiveness of antibiotic prophylaxis in cataract surgery. Ophthalmology, 123(2). Kaiser Permanente 315,246 procedure study.
- Grzybowski A, et al. (2021). Antibiotic prevention of postcataract endophthalmitis: systematic review and meta-analysis. Survey of Ophthalmology, 66(1), 98–108.
- Bergamo VC, et al. (2025). Intracameral antibiotic prophylaxis and surgical expertise: key determinants in endophthalmitis after cataract surgery. medRxiv. doi:10.1101/2025.05.19.25324616
- Barry P, et al. (2006). ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. Journal of Cataract and Refractive Surgery, 32, 407–410.
Prevention is a single injection away.
MOXGUARD by Agaaz Ophthalmics — sterile intracameral moxifloxacin 0.5mg/0.1ml — manufactured and exported from Ahmedabad, India. Used by cataract surgeons in 15+ countries.
Endophthalmitis:
The Most Feared Complication
of Cataract Surgery
And what every patient, surgeon, and distributor needs to understand about it
One in a thousand cataract surgeries ends in infection. When it does, the eye may never recover. Here is the biology, the evidence, and the three-letter word that prevents most of it.
What endophthalmitis is — and why surgeons lose sleep over it
The word comes from the Greek endon (within) and ophthalmos (eye). Endophthalmitis is an infection inside the eye — specifically a microbial colonisation of the vitreous cavity and anterior chamber. It is not an eye infection in the conventional sense. This is not pink eye. It is bacteria or fungi multiplying inside a structure that has almost no ability to defend itself.
The eye is an immunologically privileged site. It has limited access to circulating immune cells because the blood-retinal barrier, which protects it from inflammation under normal conditions, also prevents the immune system from mounting a rapid response once infection is established. By the time the eye signals distress — pain, vision loss, hypopyon — the infection is already significant.
After cataract surgery, endophthalmitis typically presents in two forms. Acute-onset (within 6 weeks of surgery, usually within days) is the most common and most dangerous — caused by virulent bacteria that enter the eye during or immediately after the procedure. Delayed-onset (weeks to months post-operatively) is typically caused by less virulent organisms and has a slower, more insidious clinical course.
This is an ophthalmic emergency
Any patient who has had cataract surgery within the past 6 weeks and presents with sudden vision worsening, eye pain, and redness should be treated as endophthalmitis until proven otherwise. This is a same-day emergency. Delay in diagnosis directly worsens the visual outcome. Immediate referral to an ophthalmologist for intravitreal antibiotic injection is the most important intervention.
How common it is — and what outcomes look like
The global incidence of post-cataract endophthalmitis sits at approximately 0.07–0.1% in surgical centres without intracameral antibiotic protocols. In absolute terms — with 20 million cataract surgeries performed annually — that translates to 14,000 to 20,000 cases of endophthalmitis every single year, worldwide. Most of these are preventable.
The AIIMS multicenter RCT published in October 2025 is the largest randomised controlled trial ever conducted on this question: 30,000 phacoemulsification cases across tertiary eye centres in India. Without intracameral prophylaxis, 16 cases of endophthalmitis occurred in 30,000 eyes (0.05%). With intracameral moxifloxacin: 6 cases in 30,000 eyes (0.02%). A 2.5-fold reduction. Statistically significant at p=0.04.
But the more sobering number is what happens when endophthalmitis does occur. The same study's follow-up data showed that at 3 months, 77% of affected eyes responded to treatment — leaving 23% that did not. Of those non-responding cases, 18% developed phthisis bulbi. One case progressed to panophthalmitis. These are not statistics. These are individual eyes that will never see again.
The antibiotic resistance question
A common concern about intracameral antibiotic use is antibiotic resistance. The AIIMS data addressed this directly: moxifloxacin resistance among causative organisms was 28.5% — the lowest of any tested fluoroquinolone. Ciprofloxacin resistance was 75%. A 2025 medRxiv preprint from a Brazilian university hospital found that moxifloxacin resistance remained stable (pre: 45.5%; post: no increase) after years of prophylactic use — contradicting fears that widespread intracameral use would rapidly select for resistant organisms.
What is actually causing the infection
Understanding the microbiology of endophthalmitis matters because it determines which antibiotics work — and why moxifloxacin's broad spectrum is clinically important.
| Organism | Frequency | Source | Moxifloxacin Susceptibility |
|---|---|---|---|
| Staphylococcus epidermidis | Most common (36–52%) | Patient's own ocular flora | High — covers well |
| Staphylococcus aureus | 10–15% | Skin, nasolacrimal flora | Good — MRSA variable |
| Streptococcal species | 9–12% | Oral/respiratory flora | Good coverage |
| Pseudomonas aeruginosa | 8–10% | Environment, water | Variable — monitor |
| Gram-negative bacilli (others) | 5–8% | Environment | Generally covers |
| Fungal (Candida, Aspergillus) | <5% (delayed onset) | Environment, systemic | Antibiotics ineffective — antifungals required |
The key clinical insight is this: the vast majority of post-cataract endophthalmitis is caused by bacteria from the patient's own periocular flora — organisms that already live on the eyelid margins, conjunctiva, and in the nasolacrimal drainage system. The bacteria do not come primarily from the surgical environment or instruments. They come from the patient.
This is why the surgery's opening step — povidone-iodine preparation of the ocular surface and surrounding skin — is irreplaceable. And it is why a drug injected inside the eye, where the flora are heading, is more effective than a drop sitting on the surface.
Who is most at risk
Not all cataract patients face equal endophthalmitis risk. The single strongest risk factor identified across multiple studies is intraoperative posterior capsular rupture — associated with a 3.68-fold increase in endophthalmitis risk in the Kaiser Permanente study of 315,246 procedures. When the posterior capsule tears, the barrier between the anterior segment and the vitreous is lost, giving bacteria direct access to a nutrient-rich, immune-privileged environment.
"Posterior capsular rupture was associated with a 3.68-fold increased risk of endophthalmitis. Intracameral antibiotic was more effective than topical agent alone. Topical antibiotic was not shown to add to the effectiveness of an intracameral regimen."
Beyond surgical complications, the systemic and ocular risk factors include:
- Clear corneal incision — compared to scleral tunnel, has higher incidence in some studies due to potential wound architecture issues
- Silicone IOL material — acrylic IOLs are associated with lower endophthalmitis rates than silicone, per ESCRS data
- Diabetes mellitus — impaired immune response, altered flora, poorer wound healing
- Blepharitis or meibomian gland dysfunction — increased periocular bacterial load
- Nasolacrimal duct obstruction — reservoir of bacteria with direct access to the ocular surface
- Immunosuppression — any cause, including systemic steroids, chemotherapy, or HIV
- High surgical volume with inadequate sterility protocols — endophthalmitis clusters have been documented after systemic contamination of intraocular solutions
The intraocular solution contamination risk
Contaminated intraocular solutions — including viscoelastics, irrigating solutions, and intracameral injectables — have caused documented endophthalmitis clusters. This is why the sourcing and manufacturing quality of these products matters beyond just price. Sterility testing, terminal sterilisation, and GMP-compliant manufacturing are not optional quality markers — they are the direct infection prevention layer at the point of most vulnerability.
Symptoms — what to look for and when to act
The classic presentation of acute post-cataract endophthalmitis is unmistakable once you know what to look for — but it is frequently misattributed to normal post-operative inflammation in its early hours, which is when the window for treatment is most critical.
The presenting triad
- Sudden vision deterioration — the patient had improving vision for days after surgery, then experiences a precipitous drop. This pattern — initial improvement followed by worsening — is the most important clinical signal.
- Pain — unlike normal post-operative discomfort, endophthalmitis pain is severe and progressive. It does not respond to over-the-counter analgesics.
- Redness with discharge — intense conjunctival injection, often with purulent or mucopurulent discharge, eyelid swelling, and chemosis.
The pathognomonic sign
Hypopyon — a visible white fluid level in the inferior anterior chamber caused by accumulation of inflammatory cells and pus. This is the hallmark slit-lamp finding of endophthalmitis. Its presence makes the diagnosis essentially certain.
What patients should do
Any patient within 6 weeks of cataract surgery who experiences sudden vision loss with or without pain should call their surgeon or go to a hospital emergency eye unit on the same day. Do not wait. Do not see if it improves overnight. The difference between presenting at 24 hours and presenting at 72 hours is, in some cases, the difference between a functioning eye and phthisis.
What actually prevents it — and what does not
Prevention of post-cataract endophthalmitis requires a layered approach. No single intervention eliminates risk entirely, but the combination of perioperative antisepsis and intracameral antibiotic prophylaxis reduces it to near-negligible levels.
1. Povidone-iodine antisepsis — non-negotiable
Application of 5% povidone-iodine to the conjunctival sac immediately before surgery remains the single most evidence-supported intervention for endophthalmitis prevention. It reduces periocular bacterial load dramatically. No other antiseptic has equivalent evidence. It is not optional.
2. Intracameral antibiotic injection — the most effective pharmacological intervention
A 2015 meta-analysis of 18 studies found that intracameral antibiotics reduced endophthalmitis incidence from 1 in 485 surgeries (without) to 1 in 2,855 surgeries (with) — a relative risk reduction to 0.12 (p<0.00001). The 2025 ScienceDirect meta-analysis of 5.6 million patients confirmed a 69% risk reduction overall, with moxifloxacin achieving an OR of 0.24 — a 76% reduction. These are among the most robust numbers in surgical prophylaxis anywhere in medicine.
3. Topical antibiotics — evidence is weaker than commonly assumed
Multiple meta-analyses have failed to demonstrate that topical antibiotic drops provide meaningful additional protection over intracameral injection alone. The Herrinton study found that combining topical and intracameral antibiotics was not more effective than intracameral alone. Yet many surgical protocols continue to prescribe topical antibiotics for weeks post-operatively, adding patient burden, cost, and preservative-related ocular surface toxicity without clear benefit.
4. Surgical technique and wound architecture
Well-constructed, self-sealing clear corneal incisions with appropriate tunnel length, and rigorous posterior capsule preservation, are the surgical foundations of endophthalmitis prevention. No antibiotic compensates for a poorly constructed wound or an unrecognised capsular complication.
MOXGUARD — Sterile Intracameral Moxifloxacin
MOXGUARD is Agaaz Ophthalmics' sterile intracameral moxifloxacin solution — formulated specifically for injection into the anterior chamber at the conclusion of cataract surgery. It is not an eye drop. It is not a topical antibiotic. It is a precisely dosed, sterile, intracameral preparation delivering the antibiotic exactly where it is needed: inside the eye, at the surgical site, at the highest-risk moment.
Moxifloxacin is a fourth-generation fluoroquinolone with bactericidal activity against both gram-positive and gram-negative organisms — covering the most common causative pathogens of post-cataract endophthalmitis. Among fluoroquinolones, it has the lowest resistance rates: 28.5% in the AIIMS trial versus 75% for ciprofloxacin. No evidence of corneal endothelial toxicity or excess postoperative inflammation was observed in the AIIMS RCT at any of its 30,000 study eyes.
More from Beyond Vision
Frequently asked questions
Endophthalmitis is a microbial infection inside the eye — specifically within the vitreous cavity and anterior chamber. After cataract surgery, it typically presents within days to weeks as a sudden, severe deterioration in vision accompanied by pain, redness, and often a visible white fluid level (hypopyon) in the anterior chamber. It is the most feared complication of cataract surgery because it can cause permanent vision loss even with prompt treatment.
Without intracameral antibiotic prophylaxis, incidence ranges from approximately 0.1% to 0.2% (1 in 500–1,000 surgeries). With intracameral antibiotic prophylaxis, this falls to approximately 0.02–0.03%. A 2025 meta-analysis of 5.6 million patients found a 69% overall risk reduction with intracameral antibiotics, with moxifloxacin specifically showing a 76% reduction. The 2025 AIIMS RCT of 30,000 cases found a 2.5-fold reduction with intracameral moxifloxacin.
The key warning signs are: sudden worsening of vision after initial improvement, significant eye pain that is getting worse rather than better, intense redness, visible pus in the eye (a white fluid level called hypopyon), and severe eyelid swelling. Any of these within 6 weeks of cataract surgery is a same-day ophthalmic emergency. Do not wait to see if symptoms improve — contact your surgeon or go to an emergency eye unit immediately.
Intracameral moxifloxacin is a sterile antibiotic solution injected directly into the anterior chamber at the end of cataract surgery — not a topical eye drop. The distinction matters enormously: topical drops sit on the ocular surface and achieve very low concentrations inside the eye. Intracameral injection delivers the antibiotic exactly where the infection risk is highest: inside the eye, immediately after the surgical wound is closed. Multiple meta-analyses confirm intracameral injection is significantly more effective than topical drops alone, and that topical antibiotics do not meaningfully add to intracameral prophylaxis.
With prompt treatment — intravitreal antibiotic injection and in some cases vitrectomy — many cases can be controlled. However, the prognosis for vision is highly variable and often poor. The 2025 AIIMS RCT found that 77% of affected eyes responded to treatment at 3 months, but 18% developed phthisis bulbi (permanent non-function) and one case progressed to panophthalmitis. Even successfully treated eyes frequently have permanently reduced visual acuity. This is why prevention via intracameral antibiotic prophylaxis is so much more important than treatment.
Peer-Reviewed References
- Sharma N, Sen A, Sharma M, et al. (2025). Efficacy of intracameral moxifloxacin in prevention of post-cataract surgery endophthalmitis: a randomized control trial. Journal of Cataract and Refractive Surgery. doi:10.1097/j.jcrs.0000000000001788
- Abu-Zaid A, et al. (2026). Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: a systematic review and meta-analysis. Frontiers in Medicine, 12:1704056. doi:10.3389/fmed.2025.1704056
- Friling E, et al. (2024). Effectiveness of intracameral antibiotics in reducing postoperative endophthalmitis risk: a meta-analysis. ScienceDirect. doi:10.1016/j.jtos.2025.01.003
- Herrinton LJ, et al. (2016). Comparative effectiveness of antibiotic prophylaxis in cataract surgery. Ophthalmology, 123(2). Kaiser Permanente 315,246 procedure study.
- Grzybowski A, et al. (2021). Antibiotic prevention of postcataract endophthalmitis: systematic review and meta-analysis. Survey of Ophthalmology, 66(1), 98–108.
- Bergamo VC, et al. (2025). Intracameral antibiotic prophylaxis and surgical expertise: key determinants in endophthalmitis after cataract surgery. medRxiv. doi:10.1101/2025.05.19.25324616
- Barry P, et al. (2006). ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. Journal of Cataract and Refractive Surgery, 32, 407–410.
Prevention is a single injection away.
MOXGUARD by Agaaz Ophthalmics — sterile intracameral moxifloxacin 0.5mg/0.1ml — manufactured and exported from Ahmedabad, India. Used by cataract surgeons in 15+ countries.
Start writing here...
Endophthalmitis After Cataract Surgery